Zhanglong Peng1, Shibani Pati, Magali J Fontaine, Kelly Hall, Anthony V Herrera, Rosemary A Kozar. 1. From the Department of Anesthesia, University of Texas, Houston, Texas (Z.P.); Blood Systems Research Institute, San Francisco, California (S.P.); Department of Pathology, University of Maryland, Baltimore, Maryland (M.J.F.); Mahtomedi, Minnesota (K.H.); Shock Trauma Center, University of Maryland, Baltimore, Maryland (A.V.H., R.A.K.).
Abstract
BACKGROUND: Clinical studies have demonstrated that the early and empiric use of plasma improves survival after hemorrhagic shock. We have demonstrated in rodent models of hemorrhagic shock that resuscitation with plasma is protective to the lungs compared with lactated Ringer's solution. As our long-term objective is to determine the molecular mechanisms that modulate plasma's protective effects in injured bleeding patients, we have used human plasma in a mouse model of hemorrhagic shock. The goal of the current experiments is to determine if there are significant adverse effects on lung injury when using human versus mouse plasma in an established murine model of hemorrhagic shock and laparotomy. METHODS: Mice underwent laparotomy and 90 minutes of hemorrhagic shock to a mean arterial pressure (MAP) of 35 ± 5 mm Hg followed by resuscitation at 1× shed blood using either mouse fresh frozen plasma (FFP), human FFP, or human lyophilized plasma. Mean arterial pressure was recorded during shock and for the first 30 minutes of resuscitation. After 3 hours, animals were killed, and lungs collected for analysis. RESULTS: There was a significant increase in early MAP when mouse FFP was used to resuscitate animals compared with human FFP or human lyophilized plasma. However, despite these differences, analysis of the mouse lungs revealed no significant differences in pulmonary histopathology, lung permeability, or lung edema between all three plasma groups. Analysis of neutrophil infiltration in the lungs revealed that mouse FFP decreased neutrophil influx as measured by neutrophil staining; however, myeloperoxidase immunostaining revealed no significant differences in between groups. CONCLUSION: The study of human plasma in a mouse model of hemorrhagic shock is feasible but does reveal some differences compared with mouse plasma-based resuscitation in physiologic measures such as MAP postresuscitation. Measures of end organ function such as lung injury appear to be comparable in this acute model of hemorrhagic shock and resuscitation.
BACKGROUND: Clinical studies have demonstrated that the early and empiric use of plasma improves survival after hemorrhagic shock. We have demonstrated in rodent models of hemorrhagic shock that resuscitation with plasma is protective to the lungs compared with lactated Ringer's solution. As our long-term objective is to determine the molecular mechanisms that modulate plasma's protective effects in injured bleedingpatients, we have used human plasma in a mouse model of hemorrhagic shock. The goal of the current experiments is to determine if there are significant adverse effects on lung injury when using human versus mouse plasma in an established murine model of hemorrhagic shock and laparotomy. METHODS:Mice underwent laparotomy and 90 minutes of hemorrhagic shock to a mean arterial pressure (MAP) of 35 ± 5 mm Hg followed by resuscitation at 1× shed blood using either mouse fresh frozen plasma (FFP), human FFP, or human lyophilized plasma. Mean arterial pressure was recorded during shock and for the first 30 minutes of resuscitation. After 3 hours, animals were killed, and lungs collected for analysis. RESULTS: There was a significant increase in early MAP when mouse FFP was used to resuscitate animals compared with human FFP or human lyophilized plasma. However, despite these differences, analysis of the mouse lungs revealed no significant differences in pulmonary histopathology, lung permeability, or lung edema between all three plasma groups. Analysis of neutrophil infiltration in the lungs revealed that mouse FFP decreased neutrophil influx as measured by neutrophil staining; however, myeloperoxidase immunostaining revealed no significant differences in between groups. CONCLUSION: The study of human plasma in a mouse model of hemorrhagic shock is feasible but does reveal some differences compared with mouse plasma-based resuscitation in physiologic measures such as MAP postresuscitation. Measures of end organ function such as lung injury appear to be comparable in this acute model of hemorrhagic shock and resuscitation.
Authors: K Wataha; T Menge; X Deng; A Shah; A Bode; J B Holcomb; D Potter; R Kozar; P C Spinella; S Pati Journal: Transfusion Date: 2013-01 Impact factor: 3.157
Authors: Michael P Chapman; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; James Chandler; John Stringham; Eduardo Gonzalez; Hunter B Moore; Anirban Banerjee; Christopher C Silliman; Angela Sauaia Journal: Shock Date: 2015-08 Impact factor: 3.454
Authors: John B Holcomb; Charles E Wade; Joel E Michalek; Gary B Chisholm; Lee Ann Zarzabal; Martin A Schreiber; Ernest A Gonzalez; Gregory J Pomper; Jeremy G Perkins; Phillip C Spinella; Kari L Williams; Myung S Park Journal: Ann Surg Date: 2008-09 Impact factor: 12.969
Authors: John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar Journal: JAMA Surg Date: 2013-02 Impact factor: 14.766
Authors: Ricky J Haywood-Watson; John B Holcomb; Ernest A Gonzalez; Zhanglong Peng; Shibani Pati; Pyong Woo Park; WeiWei Wang; Ana Maria Zaske; Tyler Menge; Rosemary A Kozar Journal: PLoS One Date: 2011-08-19 Impact factor: 3.240